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Regulation of PTH synthesis and secretion relevant to the man-
agement of secondary hyperparathyroidism in chronic kidney
disease. Small decreases in serum Ca++ and more prolonged
increases in serum phosphate (P) stimulate the parathyroid
(PT) to secrete parathyroid hormone (PTH), while 1,25(OH)2-
vitamin D3 decreases PTH synthesis and secretion. A prolonged
decrease in serum Ca++ and 1,25(OH)2D3, or increase in serum
P, such as in patients with chronic renal failure, leads to the ap-
propriate secondary increase in serum PTH. This secondary
hyperparathyroidism involves increases in PTH gene expres-
sion, synthesis, and secretion, and, if chronic, to proliferation of
the parathyroid cells. A low serum Ca++ leads to an increase in
PTH secretion, PTH mRNA stability, and parathyroid cell pro-
liferation. Pi also regulates the parathyroid in a similar man-
ner. The effect of Ca++ on the parathyroid is mediated by a
membrane Ca2+ receptor (CaR). 1,25(OH)2D3 decreases PTH
gene transcription. Ca2+ and P regulate the PTH gene post-
transcriptionally by regulating the binding of parathyroid cy-
tosolic proteins, trans factors, to a defined cis sequence in the
PTH mRNA 3′-untranslated region (UTR), thereby determin-
ing the stability of the transcript. The parathyroid trans factors
and cis elements have been defined.
Patients with chronic kidney disease (CKD) have ma-
jor disturbances in their homeostasis of calcium and phos-
phate with associated changes in vitamin D metabolism
and PTH secretion [1, 2]. The resulting diseases of their
parathyroids, bones, and arteries result in a tremendous
morbidity and mortality that have become one of the
major challenges in the management of patients with
CKD before and during their treatment by chronic dial-
ysis. Understanding the pathophysiology of the factors
involved has been of major significance to the devel-
opment of new therapeutic strategies for these patients.
However, despite the advances made, there are still large
areas where we do not have an in-depth understanding
of the mechanisms and consequences of the disturbed
mineral metabolism. Central to mineral metabolism is
the role of parathyroid hormone (PTH). Most patients
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with CKD develop secondary hyperparathyroidism, and
the mechanisms involved will be reviewed here. The
secondary hyperparathyroidism of chronic renal fail-
ure comprises increased PTH secretion, increased PTH
synthesis, and increased parathyroid cell proliferation.
Cellular and molecular studies have yielded insights
and highlighted unanswered questions into these
changes, particularly related to the regulatory actions of
1,25(OH)2 vitamin D3, calcium, and phosphate, which
have important effects at all three levels of parathyroid
dysfunction in CKD.
Vitamin D and the parathyroid
Vitamin D deficiency was known to be associated with
secondary hyperparathyroidism, and this was always con-
sidered to result from decreased absorption of calcium
from the diet with the resultant hypocalcemia stimulating
the parathyroid to secrete more PTH [3]. The parathy-
roid was not considered to be a target organ of vita-
min D. With the discovery of 1,25(OH)2-vitamin D3 as
the active metabolite of vitamin D, it became feasible to
test this accepted dogma in the laboratory. In vitro, using
bovine parathyroid cells in primary culture, 1,25(OH)2D3
decreased PTH mRNA levels [4]. In vivo studies per-
formed confirmed the physiologic relevance of these in
vitro studies [5]. 1,25(OH)2D3 in physiologically relevant
doses dramatically decreased the levels of PTH mRNA
in the parathyroids of normal rats without changing the
levels of serum calcium. We showed that the effect of
1,25(OH)2D3 on the PTH gene was transcriptional [5].
We then showed that the 1,25(OH)2D3 receptor
mRNA is expressed at a very high concentration in the
rat parathyroid, similar to its concentration in the duo-
denum, the classic vitamin D target organ [6]. Moreover,
the administration of 1,25(OH)2D3 increased the levels
of the 1,25(OH)2D3 receptor mRNA in the parathyroid,
which would then increase the amount of receptor pro-
tein in the parathryoid, and thereby amplify the effect of
circulating 1,25 (OH)2D3 on the PTH gene.
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Further studies in humans confirmed these findings in
patients with CKD [7]. Slatopolsky et al and many other
workers then showed the effectiveness of 1,25(OH)2D3
in patients with CKD to decrease PTH secretion and the
bone disease due to the high levels of circulating PTH.
1, 25(OH)2D3 also has an action to increase serum cal-
cium, and analogues of 1,25(OH)2D3 were discovered
that were less hypercalcemic than the natural compound.
In many countries, these compounds are now the main-
stay of treatment of patients with CKD.
The effect of 1,25(OH)2D3 continued to interest the
scientific community, and other interesting findings have
come to light. For instance, 1,25(OH)2D3 up-regulates
the transcription of the gene coding for the calcium re-
ceptor (CaR) in the parathyroid [8], which would make
the CaR more sensitive to the ambient serum calcium,
and thereby more avidly decrease PTH secretion at a
particular serum calcium. In addition, in the setting of
hypocalcemia, even though serum levels of 1,25(OH)2D3
increase markedly, there is a paradoxic increase in PTH
mRNA and serum PTH levels. This paradox was shown
to be due to increased concentration of a protein, calreti-
culin, in the nuclei of the parathyroids of hypocalcemic
rats, which prevented the binding of 1,25(OH)2D3 to its
receptor resulting in persistent PTH gene transcription
despite markedly elevated 1,25(OH)2D3 [9]. Of particu-
lar interest is the finding that the secondary hyperparathy-
roidism of mice with genetic deletion of the vitamin D
receptor can be corrected by a high calcium diet [10]. This
result emphasizes the dominant role of serum calcium to
regulate the parathyroid.
Another relevant observation with regard to our un-
derstanding of the role of vitamin D and the parathyroid
is the finding that in nodular hyperplastic glands there
is a decrease in the concentration of the 1,25(OH)2D3
receptor protein. The lack of 1,25(OH)2D3 receptor in
such cases is of interest because 1,25(OH)2D3 also acts
on the parathyroid to decrease parathyroid cell prolifer-
ation. In any event, the unraveling of the mechanism of
action of 1,25(OH)2D3 on the parathyroid, and its role
in the management of patients with CKD, is a classic ex-
ample of rapid translation of basic science research into
clinical applications that benefit patients. There are many
open questions in this fascinating saga that await the in-
vestigative skills of the alert clinician-scientist.
Calcium and the parathyroid
The parathyroid is geared to respond to a small de-
crease in serum Ca++ concentration by increasing PTH
secretion. It recognizes the changes in serum Ca++
concentration by a cell membrane G-protein coupled
receptor, the calcium receptor (CaR) [11]. Under normal
physiologic conditions, serum Ca++ acting at the CaR ex-
erts a natural braking action on PTH secretion, helping to
limit tonic release by parathyroid cells. The secreted PTH
then acts on its target organs, bone and kidney, to correct
the serum Ca++. The effect of a low Ca++ to stimulate
PTH secretion is quite rapid. Low Ca++ has another ef-
fect on the parathyroid gland to markedly increase PTH
gene expression and subsequent PTH synthesis; however,
this effect occurs over a time frame of hours and longer
[2]. Over an even longer time interval, low Ca++ leads
to an increase in parathyroid cell proliferation, which ini-
tially is polyclonal but, with a prolonged stimulus, may
become monoclonal [12]. In patients with CKD there is
not only a decrease in serum Ca++, but also a persistent
increase in serum phosphate, which markedly amplifies
PTH secretion, PTH gene expression, and parathyroid
cell proliferation.
Phosphate and the parathyroid
A high serum phosphorus (P) concentration has been
known for many decades to be associated with an increase
in PTH secretion. However, given uncertainty regarding
the direct effect of phosphorus on the parathyroid cell
function, this association was always considered to be
secondary to decreases in serum Ca++ and a decrease in
serum 1,25(OH)2D3 levels [13]. It was shown clinically in
CKD patients and in laboratory animals with experimen-
tal uremia that correction of the serum P with no changes
in serum Ca++ or 1,25(OH)2D3 levels was able to cor-
rect the serum PTH levels. Kilav et al showed in careful
studies in rats with normal renal function that serum P
regulated PTH mRNA and serum PTH levels indepen-
dently of changes in either serum Ca++ or 1,25(OH)2D3
levels [14]. In vitro studies from a number of laboratories
have shown a direct effect of P on the parathyroid to reg-
ulate PTH secretion [15, 16] by a mechanism involving
inhibition of cytosolic phospholipase A2 (cPLA2) [17].
Regulation of parathyroid hormone gene expression by
serum calcium and phosphate
In uremic secondary hyperparathyroidism, PTH
mRNA levels are increased [18]. Research into the reg-
ulation of PTH gene expression has been crucial to
understanding the pathogenesis of secondary hyper-
parathyroidism. Because the amount of preformed, ma-
ture PTH is limited and degradation of the hormone is
rapid, much of the regulatory control of PTH occurs at
the level of gene expression [19].
Like 1,25(OH)2D3, the concentrations of Ca++ and
P regulate the abundance of PTH mRNA. Low serum
Ca++ and high serum P increase PTH mRNA levels in
the rat, and dietary manipulation of these minerals is
sufficient to trigger the change [14, 20, 21]. However,
unlike 1,25(OH)2D3, the regulatory actions of serum
Ca++ and P are at the post-transcriptional level [14, 20].
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Investigation of these post-transcriptional mechanisms
has proved particularly interesting.
Mechanism for post-transcriptional regulation of
parathyroid hormone gene expression by serum calcium
and phosphate
PTH mRNA stability is determined by the regulated
binding of protective factors to a defined region in the
PTH mRNA 3′-untranslated region (UTR) that prevents
ribonucleases from degrading the RNA. Serum Ca++ and
P are important regulators of these cytosolic factors, help-
ing to maintain the normal balance between degradation
and protection. Thus, the changes in serum Ca++ and P
levels in patients with CKD lead to an increased PTH
mRNA stability and secondary hyperparathyroidism.
Parathyroid cytosolic proteins bind within the terminal
60 nucleotide sequence of the 3′ untranslated region (3′-
UTR) of the PTH mRNA, and Ca++ and P regulate this
binding [20]. Using ultraviolet cross-linking, we demon-
strated changes in the binding of parathyroid cytosolic
protein to the 3′-UTR in response to dietary-induced
hypocalcemia and hypophosphatemia [20]. Protein ex-
tracts from hypocalcemic rats showed greater binding
than did protein extracts from control rats, whereas
extracts from hypophosphatemic rats showed reduced
binding. This oppositional regulation of protein-mRNA
binding by serum calcium and phosphate was dependent
on the presence of the 3′-UTR.
Further experiments linked these influences of Ca++
and P on protein-RNA binding to changes in PTH mRNA
stability. Unfortunately, there is no parathyroid cell line
with which to measure PTH mRNA half life in vivo, but
using an in vitro degradation assay, it was discovered that
cytosolic proteins from hypocalcemic rats stabilize PTH
mRNA, greatly increasing its half life. In contrast, cytoso-
lic proteins from hypophosphatemic rats led to marked,
rapid degradation of the transcript. These regulatory ef-
fects of Ca++ and P on PTH mRNA half life require the
same 60 nucleotide terminal region of the 3′-UTR needed
for cytosolic protein binding.
The presence of a common sequence mediating
parathyroid cytosolic protein binding and PTH mRNA
stability supports a functional link whereby transcript sta-
bility is mediated by the binding of cytosolic proteins to
the 3′-UTR. Moreover, the dual regulatory actions of
Ca++ and P on binding and stability also require this
sequence, suggesting that these minerals produce their
effects on PTH mRNA stability through changes in the
binding of protective proteins.
A different pattern of effects on binding and stability
occurs in a rodent model of chronic renal failure (rats with
5/6 nephrectomy). Cytosolic proteins from 5/6 nephrec-
tomized rats do not show differences in PTH mRNA
binding relative to control cytosolic proteins, but they
nonetheless stabilize PTH mRNA [18]. These findings
suggest that the increased levels of PTH mRNA in the
setting of chronic renal failure are due primarily to a re-
duction in cytosolic ribonuclease activity, resulting in a
more stable PTH transcript.
Thus, the effects of hypocalcemia, hyperphosphatemia,
and chronic renal failure on PTH gene expression all
occur at the level of PTH mRNA stability, and more
precisely, the effects are mediated by changes in PTH
transcript protective and degrading proteins. Hypocal-
cemia and hypophosphatemia affect the binding of cy-
tosolic protective factors and, consequently, PTH mRNA
stability. Hypocalcemia stabilizes PTH mRNA by in-
creasing the binding of cytosolic protective factors,
whereas hypophosphatemia has the opposite effect. In
rats with chronic renal failure, there is greater PTH
mRNA stability by virtue of a decrease in the activity
of degrading factors.
Identity of parathyroid cytosolic protective proteins
The importance of cytosolic protective factors (trans
factors) to the stabilization of PTH mRNA is further
demonstrated by the destabilizing effect of adding ex-
cess PTH mRNA 3′-UTR to an in vitro degradation as-
say [20]. Addition of excess PTH mRNA 3′-UTR, or a
smaller 63 nucleotide transcript sufficient for binding, re-
sults in rapid degradation of mRNA, presumably by caus-
ing competition for the binding of stabilizing protective
factors. The identity of these protective factors is of great
interest. Sela-Brown et al [22] have identified one such
protein, adenosine-uridine-rich binding protein (AUF1).
AUF1 was identified by sequencing a major band gen-
erated from an in vitro degradation assay of parathyroid
protein extracts and the PTH transcript. Recombinant
AUF1 stabilized PTH mRNA in this same assay. How-
ever, it is not yet clear how AUF1 may mediate the effects
of serum Ca++ and P on PTH mRNA stability.
Identification of the cis acting sequence in the PTH
mRNA 3′-UTR
We then defined the cis sequence in the PTH mRNA
3′-UTR to which the trans acting parathyroid proteins
bind and determines the stability of the PTH transcript
[23]. We have identified the minimal sequence for pro-
tein binding in the PTH mRNA 3′-UTR and determined
its functionality. A minimum sequence of 26 nucleotides
was sufficient for RNA-protein binding, and competed
for binding of the full-length 3′-UTR by RNA elec-
trophoretic mobility shift assay (REMSA). Antisense
oligonucleotides to different regions of the conserved
RNA element further identified this binding. The el-
ement’s sequence was preserved among species. The
rat PTH mRNA 3′-UTR is 234 nucleotides long. Se-
quence analysis of the PTH mRNA 3′-UTR of different
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species revealed a preservation of the 26 nucleotide core
protein-binding element in rat, murine, human, and ca-
nine 3′-UTRs. To study the functionality of the sequence
in the context of another RNA, a 63 bp cDNA PTH se-
quence consisting of the 26 nucleotides and flanking re-
gions was fused to the growth hormone (GH) cDNA. This
allowed us to use an in vitro degradation assay to deter-
mine the effect of parathyroid cytosolic proteins on the
stability of RNA transcripts for PTH, GH, and a chimeric
GH-PTH 63 nucleotide. The PTH transcript was stabi-
lized by parathyroid proteins from rats fed a low calcium
diet, and destabilized by proteins from rats fed a low phos-
phorus diet, correlating with PTH mRNA levels in vivo.
GH transcript was more stable than PTH RNA, and was
not affected by parathyroid proteins from the rats on dif-
ferent diets. The chimeric GH transcript was stabilized
by low calcium diet parathyroid proteins, and destabi-
lized by low phosphate diet parathyroid proteins, similar
to the PTH full-length transcript. Therefore, the 63 nu-
cleotid protein binding region of the PTH mRNA 3′-UTR
is both necessary and sufficient to regulate RNA stability,
and to confer responsiveness to changes in parathyroid
proteins by calcium and phosphate [23]. The PTH mRNA
3′-UTR binding element is a type III AU-rich element
that, unlike most AU-rich elements, has an open struc-
ture [24]. Thus, it is able to regulate mRNA stability in
the absence of a defined structure.
PT cell proliferation
Parathyroid cells divide infrequently [25]. However,
the parathyroid cell retains the latent ability to prolif-
erate into large hyperfunctioning glands in a number of
clinical conditions. A common situation is that of the sec-
ondary hyperparathyroidism that occurs in most patients
with CKD. Persistently low serum Ca++ or high serum
P levels are the major factors leading to parathyroid cell
proliferation [26]. Treatment with 1,25(OH)-vitamin D
directly decreases PTH gene transcription and parathy-
roid cell proliferation [27, 28]. However, vitamin D
deficiency alone may cause parathyroid cells to prolifer-
ate through an indirect mechanism mediated by chronic
hypocalcemia [10]. Calcium is the major regulator of the
parathyroid, at the levels of secretion, gene expression,
and cell proliferation. In vivo, hypocalcemia leads to a
profound increase in parathyroid cell proliferation [26],
and to investigate the mechanism, in vitro studies have
been performed. However, it is difficult to extrapolate
from in vitro studies on parathyroid cells because in pri-
mary cultures of bovine parathyroid cells there is a down-
regulation of the CaR [29, 30].
Studies of rats with chronic renal failure due to 5/6
nephrectomy reveal sensitive regulation of parathyroid
cell proliferation by serum P levels [26]. In rodents, a low
P diet has been shown to prevent the 5-fold increase in
parathyroid cell proliferation associated with chronic re-
nal failure. This regulation by P is bidirectional; a high P
diet increases parathyroid cell proliferation to levels that
are significantly greater than those in rats with experi-
mental uremia fed a normal diet.
Consistent with the patterns of regulation of PTH se-
cretion and PTH gene expression, serum Ca++ regulates
parathyroid proliferation in a fashion opposite to serum
P. A low calcium diet markedly increases parathyroid cell
proliferation [26], and in rats with chronic renal failure,
administration of a calcimimetic compound that binds to
the CaR attenuates the increase in parathyroid cell pro-
liferation [31].
Other research has begun to identify additional reg-
ulators of parathyroid cell proliferation. These regula-
tors include the endothelin receptor and the epidermal
growth factor receptor. Antagonism of these signaling
pathways decreases parathyroid cell proliferation in ro-
dent models of renal failure [28, 32]. Collectively, these
findings suggest several potential targets for the preven-
tion of parathyroid hyperplasia in the setting of secondary
hyperparathyroidism, including Ca++, P, endothelin, and
epidermal growth factor signaling.
CONCLUSION
In diseases such as chronic renal failure, secondary hy-
perparathyroidism involves abnormalities in PTH secre-
tion, synthesis, and cellular proliferation. Progress has
been made in understanding how Ca++, P, and vitamin D
regulate the synthesis and secretion of PTH, as well as the
proliferation of the parathyroid cells. A more complete
understanding of how the parathyroid gland is regulated
at each level will eventually lead to additional therapeutic
options for the clinical management of secondary hyper-
parathyroidism in chronic kidney disease.
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